SEC Form 4 · accession 0001209191-18-009677
ACHILLION PHARMACEUTICALS INC · ACHN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mary Kay Fenton
Officer — Chief Financial Officer
Period of report
Feb 9, 2018
Accepted (ET)
Feb 13, 2018 · 5:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070336
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock OptionF1 | $2.90 | Feb 9, 2018 | A | 250,000 | A | — | Feb 9, 2028 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter.